 |
 |

Nylidrin Hydrochloride in Senile Arteriosclerosis
KEITH R. TREPTOW, MD;
D. CRAIG AFFLECK, PhD;
C. ALLEN ROEHL, PhD;
WARNER M. SOELLING, MD
Arch Neurol. 1963;9(2):142-146.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
The scope of the problem of senile and arteriosclerotic brain syndromes is suggested by population and state hospital statistics. Between 1900 and 1950 the population of the United States doubled, while the number of persons aged 65 or over increased fivefold. Presently, 30% of the patients in state mental hospitals are over 65; of this group 41% are senile-arteriosclerotic. Nearly one third (27%) of all first admissions are over 65; of these over 80% are senile-arteriosclerotic.2
Because of the assumption that arteriosclerotic patients would benefit from improved cerebral circulation, vasodilators such as tolazoline hydrochloride (Priscoline) and 3-pyridinemethanol (Roniacol, the alcohol corresponding to nicotinic acid) have had extensive clinical use. That these agents actually do not increase cerebral blood flow has been established.12
Recent work with the vasodilating agent isoxsuprine hydrochloride (Vasodilan) demonstrated its effectiveness in increasing cerebral blood flow.5 A recent study of this drug 1 indicated
. . . [Full Text PDF of this Article]
Footnotes
Submitted for publication April 20, 1963; accepted May 17, 1963.
Nebraska Psychiatric Institute, University of Nebraska College of Medicine (Dr. Treptow).
This study was supported in part by the National Institute of Mental Health, Public Health Service research grant MY-2784, and the US Vitamin & Pharmaceutical Corporation.
The US Vitamin & Pharmaceutical Corporation supplied the drug and the placebo.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|